| 11/16/2026 10:52 AM | Dyne Therapeutics (1818794) Subject WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by | Form SCHEDULE 13G | |
| 11/05/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/22/2026 3:10 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/06/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/29/2026 3:10 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/08/2026 3:38 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:39 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:13 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:14 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/17/2026 4:30 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:06 PM | Dyne Therapeutics (1818794) Issuer Lucera Erick (1697616) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 4:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 4:47 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 4:47 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:04 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 3:51 PM | Atlas Venture Fund XI, L.P. (1708269) Filed by Dyne Therapeutics (1818794) Subject | Form SCHEDULE 13G/A | |
| 08/13/2026 11:47 AM | Dyne Therapeutics (1818794) Subject Janus Henderson Group Ltd. (1274173) Filed by | Form SCHEDULE 13G/A | |
| 08/06/2026 9:20 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 07/22/2026 4:19 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/22/2026 4:21 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/21/2026 4:22 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/20/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:35 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/07/2026 4:05 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:05 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 6:05 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:49 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
You missed yesterday's deadline… (Ad) In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years.
While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. See which company controls this entire energy discovery now. |
| 06/29/2026 4:50 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 7:40 AM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/25/2026 4:28 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:11 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:32 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:33 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 3:27 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:25 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:26 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:19 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/23/2026 3:07 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/17/2026 3:03 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/09/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Stehman-Breen Catherine (1702233) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Incerti Carlo (1915358) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:15 PM | Dyne Therapeutics (1818794) Issuer HURWITZ EDWARD (1211840) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:06 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:36 AM | Dyne Therapeutics (1818794) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:04 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:55 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2026 3:57 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2026 3:42 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:13 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 05/05/2026 3:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:36 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:37 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Your book is inside (Ad) The "Sucker's Bet" Most New Options Traders Fall For
Most people who try options lose money the same way.
They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter.
Normally $29.97. Free today. Download your copy now. |
| 05/04/2026 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/30/2026 4:22 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:56 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 5:15 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/27/2026 3:48 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |